Adult Vaccines for Respiratory Season Influenza, COVID-19, RSV, and Pneumococcal 2024-2025

Caitlin Anton

Adult Vaccine Program Manager

November 21, 2024



Objectives

Overview of respiratory season vaccines

Latest schedules and recommendations

Strategies for improving patient uptake

Influenza Vaccine for Adults

- The recombinant flu vaccine is approved for people 18 years and older, and the adjuvanted and high-dose inactivated vaccines are approved for people 65 years and older.
- For people younger than 65 years, CDC does not recommend any one flu vaccine over another.
- For adults 65 years and older, there are 3 flu vaccines that are preferentially recommended.
 - Fluzone High-Dose inactivated flu vaccine,
 - Flublok recombinant flu vaccine, and
 - Fluad adjuvanted inactivated flu vaccine.
- If none of the 3 flu vaccines preferentially recommended for people 65 years and older is available at the time of administration, people in this age group can get any other ageappropriate flu vaccine instead.



COVID-19 Vaccine for Adults

Updated 2024-2025 COVID-19 Vaccine

- Three COVID-19 vaccines are available for use in the United States. There is no preference for one vaccine over the other when more than one vaccine is recommended for an age group.
- The 2024–2025 COVID-19 vaccines more closely target the JN.1 lineage of the Omicron variant.
 COVID-19 vaccines are updated to give you the best protection from the currently circulating strains.
- It is important to get the updated 2024–2025 COVID-19 vaccine for those who are aged 65 and older, are at high risk for severe COVID-19, or have never received a COVID-19 vaccine.

You are up to date when you have received:

- 1 dose of the 2024–2025 Moderna COVID-19 vaccine OR
- 1 dose of the 2024–2025 Pfizer-BioNTech COVID-19 vaccine OR
- 1 dose of the 2024–2025 Novavax vaccine unless you are receiving a COVID-19 vaccine for the very first time. If you have never received any COVID-19 vaccine and you choose to get Novavax, you need 2 doses of 2024–2025 Novavax COVID-19 vaccine to be up to date.

Co-Administration: Safe with flu and RSV

RSV Vaccine for Adults



CDC recommends everyone ages 75 and older get an RSV vaccine.



CDC recommends adults ages 60–74 who are at increased risk of severe RSV disease get an RSV vaccine.




The RSV vaccine is not currently an annual vaccine. If you have received an RSV vaccine already (including last year), you should not get another RSV vaccine at this time.



You can get one at any time, but the best time to get vaccinated is in late summer and early fall.

RSV Vaccine for Adults



Pneumococcal Vaccine for Adults

Who should get vaccinated:

- All adults 50 years or older
- 19 through 49 years old with certain risk conditions
- ➤ In October 2024, the Advisory Committee on Immunization Practices (ACIP) voted to lower the age for routine pneumococcal vaccination from 65 to 50 years old.
- > For adults who have not previously received a PCV:
 - Administer a single dose of PCV15, PCV20, or PCV21.
 - If PCV15 is used, follow with a dose of PPSV23 at least one year later
- For adults with prior vaccination:
 - Recommendations may vary based on previous vaccine types and timing.
- App available to interpret recommendations
 - CDC offers PneumoRecs VaxAdvisor as a free app to quickly and easily provide patient-specific pneumococcal vaccine guidance. It's available for download for iOS and Android mobile devices. There's also a web-based version that doesn't require a download.

317-Funded Vaccines and Budget



Available Vaccines:

Flu, COVID-19, and RSV vaccines are all available to eligible uninsured or underinsured adults through the 317 Adult Vaccine Program.



Prebooking Process:

Prebooking is done twice a year.

Orders are limited based on the available budget.

MIP staff place the vaccine orders on provider's behalf to prevent shortages or overordering.



Budget Constraints:

The 317 Program operates with a limited budget

Providers should prioritize high-risk patients and manage inventory carefully to minimize wastage.

Given the limited budget we receive it is crucial to ensure 317 vaccine is only given to adults who are eligible (19+ who are insured or underinsured).

Other Resources for Adult Vaccination

Several pharmaceutical companies offer patient assistance programs to help adults access vaccines at reduced or no cost. Here are a few that offer some of the respiratory vaccines:

1. Merck Vaccine Patient Assistance Program

- Vaccines Covered: Offers vaccines such as Gardasil 9 (HPV), Pneumovax 23 (Pneumococcal) and Varivax (chickenpox).
- Eligibility: Uninsured adults who meet income requirements.
- Application Process: Patients or providers can apply through the program's website.

2. Pfizer RxPathways

- Vaccines Covered: Includes Prevnar 13 and Prevnar 20 (pneumococcal), COVID-19, among others.
- Eligibility: Uninsured or underinsured individuals who meet income guidelines.
- Application Process: Applications can be submitted online or via mail.

3. Moderna's Patient Assistance Program

- Vaccine Covered: Spikevax COVID-19 Vaccine
- Eligibility: Uninsured or underinsured individuals in the U.S.
- Where to go: Find a Clinic | National Association of Free & Charitable Clinics

Strategies for Increasing Vaccine Uptake

Awareness & Education:

- Educate adults on the risks of respiratory illnesses and vaccine benefits.
- Use culturally appropriate materials for diverse populations.
- Leverage seasonal campaigns for influenza, COVID-19 and RSV awareness.

Provider Engagement:

- Train staff on vaccine recommendations and effective patient communication.
- Implement standing orders for respiratory vaccine administration.
- Use ImmPact and EHR for missed opportunities.

Reduce Barriers to Access:

- Cost:
 - Enroll in MIP's 317 Adult Vaccine Program to receive adult vaccinations
 - Assist patients in applying to Patient Assistance Programs
- Location: Increase vaccination sites in rural and underserved areas
- **Convenience:** Offer evening/weekend hours and walk-in/drive-through clinics to accommodate working adults.

Summary

- Respiratory vaccine are critical for protecting adults, particularly those at high-risk, during the 2024-25 season.
- Focusing on education, provider engagement and removing barriers, we can improve vaccine uptake and reduce the burden of respiratory diseases.
- Let's work together to ensure that no adult is left unprotected!



Resources

- 1. Centers for Disease Control and Prevention (CDC):
 - General Vaccine Guidelines:

https://www.cdc.gov/vaccines

ACIP Recommendations for COVID-19:

https://www.cdc.gov/media/releases/2024/s1023-covid-19-vaccine.html

ACIP Recommendations for Pneumococcal:

https://www.cdc.gov/media/releases/2024/s1023-pneumococcal-vaccination.html

- 2. National Association of Free & Charitable Clinics:
 - Locate Free Vaccine Clinics:

https://nafcclinics.org/find-clinic

- 3. PneumoRecs VaxAdvisor App (CDC):
 - Tool for Pneumococcal Vaccine Recommendations:

https://www.cdc.gov/vaccines/vpd/pneumo/hcp/pneumoapp.html

- 4. Patient Assistance Programs by Pharmaceutical Companies:
 - Merck Vaccine Patient Assistance Program:

https://www.merckhelps.com

Pfizer RxPathways:

https://www.pfizerrxpathways.com

Moderna Patient Assistance Program:

https://www.modernatx.com

Questions?

Caitlin Anton Adult Vaccine Program Manager

MEAdultVaccine@maine.gov

